Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
Contrary to tandem autologous transplant (auto-auto), autologous followed by reduced intensity conditioning allogenic transplantation (auto-allo) offers graft-versus-myeloma (GVM) effect but with higher toxicity. Trials comparing these two strategies relied on availability of HLA-matched sibling don...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2020-09, Vol.55 (9), p.1810-1816 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1816 |
|---|---|
| container_issue | 9 |
| container_start_page | 1810 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 55 |
| creator | Costa, Luciano J. Iacobelli, Simona Pasquini, Marcelo C. Modi, Riddhi Giaccone, Luisa Blade, Joan Schonland, Stefan Evangelista, Andrea Perez-Simon, Jose A. Hari, Parameswaran Brown, Elizabeth E. Giralt, Sergio A. Patriarca, Francesca Stadtmauer, Edward A. Rosinol, Laura Krishnan, Amrita Y. Gahrton, Gösta Bruno, Benedetto |
| description | Contrary to tandem autologous transplant (auto-auto), autologous followed by reduced intensity conditioning allogenic transplantation (auto-allo) offers graft-versus-myeloma (GVM) effect but with higher toxicity. Trials comparing these two strategies relied on availability of HLA-matched sibling donors for arm allocation (biological randomization) and yielded conflicting results. A pooled analysis of multiple trials with extended follow up provides an opportunity to compare these strategies. We obtained individual patient data from participants of four trials comparing auto-auto vs. auto-allo after induction therapy. There were 899 patients in auto-auto and 439 in auto-allo. Median follow up of survivors was 118.5 months. Median overall survival (OS) was 78.0 months in auto-auto and 98.3 months in auto-allo (HR = 0.84,
P
= 0.02). OS was 36.4% vs. 44.1% at 10 years (
P
= 0.01) for auto-auto and auto-allo, respectively. Progression-free survival was also improved in auto-allo (HR = 0.84,
P
= 0.004). Risk of non-relapse mortality was higher in auto-allo (10 year 8.3% vs. 19.7%,
P
|
| doi_str_mv | 10.1038/s41409-020-0887-4 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_472036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A633782930</galeid><sourcerecordid>A633782930</sourcerecordid><originalsourceid>FETCH-LOGICAL-c579t-8ec6088d11b67cbb54159bc6e32733c6fde78e7ab7cd03539815cc1ec59c295c3</originalsourceid><addsrcrecordid>eNp9kktv1DAUhSMEokPhB7BBkZAQGw9-P5ZVRQFpKjawthznZiYlsYfYmar_vh7NUKYIUBZ2nO_c-Nx7quo1wUuCmf6QOOHYIEwxwlorxJ9UC8KVRIJJ8bRaYCo1Ykyas-pFSjcYE86xeF6dMUq1FFguqriKYY0yTGOd5mnX79xQx64mjOn6-rreutxDyKnOE7gMbX3b502dXWhhrN2c4xDXcU71Li1PXpEbygYC9L4IXUjbwYVcSsXwsnrWuSHBq-N6Xn2_-vjt8jNaff305fJihbxQJiMNXhZLLSGNVL5pBCfCNF4Co4oxL7sWlAblGuVbzAQzmgjvCXhhPDXCs_MKHeqmW9jOjd1O_eimOxtdb49HP8oOLFcUM1n49wd-O8WfM6Rsxz55GMrFoTiylGkjDZNcFPTtH-hNnKdQ3FjKlcCUSKP-TzEly-jMSa21G8D2oYulX37_a3shGVOaGoYLtfwLVZ4yhd7HAF1fzh8J3p0INuCGvElxmPcTSI9BcgD9FFOaoHtoFMF2nzF7yJgtGbP7jFleNG-OzuZmhPZB8StUBaDH3pdPYQ3Tb-v_rnoP8kXaAw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2437641495</pqid></control><display><type>article</type><title>Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SWEPUB Freely available online</source><source>SpringerLink Journals - AutoHoldings</source><creator>Costa, Luciano J. ; Iacobelli, Simona ; Pasquini, Marcelo C. ; Modi, Riddhi ; Giaccone, Luisa ; Blade, Joan ; Schonland, Stefan ; Evangelista, Andrea ; Perez-Simon, Jose A. ; Hari, Parameswaran ; Brown, Elizabeth E. ; Giralt, Sergio A. ; Patriarca, Francesca ; Stadtmauer, Edward A. ; Rosinol, Laura ; Krishnan, Amrita Y. ; Gahrton, Gösta ; Bruno, Benedetto</creator><creatorcontrib>Costa, Luciano J. ; Iacobelli, Simona ; Pasquini, Marcelo C. ; Modi, Riddhi ; Giaccone, Luisa ; Blade, Joan ; Schonland, Stefan ; Evangelista, Andrea ; Perez-Simon, Jose A. ; Hari, Parameswaran ; Brown, Elizabeth E. ; Giralt, Sergio A. ; Patriarca, Francesca ; Stadtmauer, Edward A. ; Rosinol, Laura ; Krishnan, Amrita Y. ; Gahrton, Gösta ; Bruno, Benedetto</creatorcontrib><description>Contrary to tandem autologous transplant (auto-auto), autologous followed by reduced intensity conditioning allogenic transplantation (auto-allo) offers graft-versus-myeloma (GVM) effect but with higher toxicity. Trials comparing these two strategies relied on availability of HLA-matched sibling donors for arm allocation (biological randomization) and yielded conflicting results. A pooled analysis of multiple trials with extended follow up provides an opportunity to compare these strategies. We obtained individual patient data from participants of four trials comparing auto-auto vs. auto-allo after induction therapy. There were 899 patients in auto-auto and 439 in auto-allo. Median follow up of survivors was 118.5 months. Median overall survival (OS) was 78.0 months in auto-auto and 98.3 months in auto-allo (HR = 0.84,
P
= 0.02). OS was 36.4% vs. 44.1% at 10 years (
P
= 0.01) for auto-auto and auto-allo, respectively. Progression-free survival was also improved in auto-allo (HR = 0.84,
P
= 0.004). Risk of non-relapse mortality was higher in auto-allo (10 year 8.3% vs. 19.7%,
P
< 0.001), while risk of disease progression was higher in auto-auto (10 year 77.2% vs. 61.6%,
P
< 0.001). Median post relapse survival was 41.5 months in auto-auto and 62.3 months in auto-allo (HR = 0.71,
P
< 0.001). This supports the existence of durable GVM effect enhancing myeloma control with subsequent therapies.</description><identifier>ISSN: 0268-3369</identifier><identifier>ISSN: 1476-5365</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-020-0887-4</identifier><identifier>PMID: 32286506</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/2779/109/1942 ; 692/699/67/1059/2325 ; 692/699/67/1990/804 ; Autografts ; Care and treatment ; Cell Biology ; Clinical trials ; Disease-Free Survival ; Graft vs Host Disease ; Health risks ; Hematology ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Histocompatibility antigen HLA ; Humans ; Induction therapy ; Internal Medicine ; Medicine ; Medicine & Public Health ; Multiple myeloma ; Myeloma ; Neoplasm Recurrence, Local ; Patient outcomes ; Public Health ; Risk assessment ; Stem cell transplantation ; Stem Cells ; Survival ; Toxicity ; Transplantation ; Transplantation Conditioning ; Transplantation, Autologous ; Transplantation, Homologous ; Transplants & implants</subject><ispartof>Bone marrow transplantation (Basingstoke), 2020-09, Vol.55 (9), p.1810-1816</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c579t-8ec6088d11b67cbb54159bc6e32733c6fde78e7ab7cd03539815cc1ec59c295c3</citedby><cites>FETCH-LOGICAL-c579t-8ec6088d11b67cbb54159bc6e32733c6fde78e7ab7cd03539815cc1ec59c295c3</cites><orcidid>0000-0001-5362-2469</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41409-020-0887-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41409-020-0887-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,552,778,782,883,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32286506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:143449337$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Costa, Luciano J.</creatorcontrib><creatorcontrib>Iacobelli, Simona</creatorcontrib><creatorcontrib>Pasquini, Marcelo C.</creatorcontrib><creatorcontrib>Modi, Riddhi</creatorcontrib><creatorcontrib>Giaccone, Luisa</creatorcontrib><creatorcontrib>Blade, Joan</creatorcontrib><creatorcontrib>Schonland, Stefan</creatorcontrib><creatorcontrib>Evangelista, Andrea</creatorcontrib><creatorcontrib>Perez-Simon, Jose A.</creatorcontrib><creatorcontrib>Hari, Parameswaran</creatorcontrib><creatorcontrib>Brown, Elizabeth E.</creatorcontrib><creatorcontrib>Giralt, Sergio A.</creatorcontrib><creatorcontrib>Patriarca, Francesca</creatorcontrib><creatorcontrib>Stadtmauer, Edward A.</creatorcontrib><creatorcontrib>Rosinol, Laura</creatorcontrib><creatorcontrib>Krishnan, Amrita Y.</creatorcontrib><creatorcontrib>Gahrton, Gösta</creatorcontrib><creatorcontrib>Bruno, Benedetto</creatorcontrib><title>Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Contrary to tandem autologous transplant (auto-auto), autologous followed by reduced intensity conditioning allogenic transplantation (auto-allo) offers graft-versus-myeloma (GVM) effect but with higher toxicity. Trials comparing these two strategies relied on availability of HLA-matched sibling donors for arm allocation (biological randomization) and yielded conflicting results. A pooled analysis of multiple trials with extended follow up provides an opportunity to compare these strategies. We obtained individual patient data from participants of four trials comparing auto-auto vs. auto-allo after induction therapy. There were 899 patients in auto-auto and 439 in auto-allo. Median follow up of survivors was 118.5 months. Median overall survival (OS) was 78.0 months in auto-auto and 98.3 months in auto-allo (HR = 0.84,
P
= 0.02). OS was 36.4% vs. 44.1% at 10 years (
P
= 0.01) for auto-auto and auto-allo, respectively. Progression-free survival was also improved in auto-allo (HR = 0.84,
P
= 0.004). Risk of non-relapse mortality was higher in auto-allo (10 year 8.3% vs. 19.7%,
P
< 0.001), while risk of disease progression was higher in auto-auto (10 year 77.2% vs. 61.6%,
P
< 0.001). Median post relapse survival was 41.5 months in auto-auto and 62.3 months in auto-allo (HR = 0.71,
P
< 0.001). This supports the existence of durable GVM effect enhancing myeloma control with subsequent therapies.</description><subject>692/308/2779/109/1942</subject><subject>692/699/67/1059/2325</subject><subject>692/699/67/1990/804</subject><subject>Autografts</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Clinical trials</subject><subject>Disease-Free Survival</subject><subject>Graft vs Host Disease</subject><subject>Health risks</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Induction therapy</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multiple myeloma</subject><subject>Myeloma</subject><subject>Neoplasm Recurrence, Local</subject><subject>Patient outcomes</subject><subject>Public Health</subject><subject>Risk assessment</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival</subject><subject>Toxicity</subject><subject>Transplantation</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Autologous</subject><subject>Transplantation, Homologous</subject><subject>Transplants & implants</subject><issn>0268-3369</issn><issn>1476-5365</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>D8T</sourceid><recordid>eNp9kktv1DAUhSMEokPhB7BBkZAQGw9-P5ZVRQFpKjawthznZiYlsYfYmar_vh7NUKYIUBZ2nO_c-Nx7quo1wUuCmf6QOOHYIEwxwlorxJ9UC8KVRIJJ8bRaYCo1Ykyas-pFSjcYE86xeF6dMUq1FFguqriKYY0yTGOd5mnX79xQx64mjOn6-rreutxDyKnOE7gMbX3b502dXWhhrN2c4xDXcU71Li1PXpEbygYC9L4IXUjbwYVcSsXwsnrWuSHBq-N6Xn2_-vjt8jNaff305fJihbxQJiMNXhZLLSGNVL5pBCfCNF4Co4oxL7sWlAblGuVbzAQzmgjvCXhhPDXCs_MKHeqmW9jOjd1O_eimOxtdb49HP8oOLFcUM1n49wd-O8WfM6Rsxz55GMrFoTiylGkjDZNcFPTtH-hNnKdQ3FjKlcCUSKP-TzEly-jMSa21G8D2oYulX37_a3shGVOaGoYLtfwLVZ4yhd7HAF1fzh8J3p0INuCGvElxmPcTSI9BcgD9FFOaoHtoFMF2nzF7yJgtGbP7jFleNG-OzuZmhPZB8StUBaDH3pdPYQ3Tb-v_rnoP8kXaAw</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Costa, Luciano J.</creator><creator>Iacobelli, Simona</creator><creator>Pasquini, Marcelo C.</creator><creator>Modi, Riddhi</creator><creator>Giaccone, Luisa</creator><creator>Blade, Joan</creator><creator>Schonland, Stefan</creator><creator>Evangelista, Andrea</creator><creator>Perez-Simon, Jose A.</creator><creator>Hari, Parameswaran</creator><creator>Brown, Elizabeth E.</creator><creator>Giralt, Sergio A.</creator><creator>Patriarca, Francesca</creator><creator>Stadtmauer, Edward A.</creator><creator>Rosinol, Laura</creator><creator>Krishnan, Amrita Y.</creator><creator>Gahrton, Gösta</creator><creator>Bruno, Benedetto</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0001-5362-2469</orcidid></search><sort><creationdate>20200901</creationdate><title>Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation</title><author>Costa, Luciano J. ; Iacobelli, Simona ; Pasquini, Marcelo C. ; Modi, Riddhi ; Giaccone, Luisa ; Blade, Joan ; Schonland, Stefan ; Evangelista, Andrea ; Perez-Simon, Jose A. ; Hari, Parameswaran ; Brown, Elizabeth E. ; Giralt, Sergio A. ; Patriarca, Francesca ; Stadtmauer, Edward A. ; Rosinol, Laura ; Krishnan, Amrita Y. ; Gahrton, Gösta ; Bruno, Benedetto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c579t-8ec6088d11b67cbb54159bc6e32733c6fde78e7ab7cd03539815cc1ec59c295c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/308/2779/109/1942</topic><topic>692/699/67/1059/2325</topic><topic>692/699/67/1990/804</topic><topic>Autografts</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Clinical trials</topic><topic>Disease-Free Survival</topic><topic>Graft vs Host Disease</topic><topic>Health risks</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Induction therapy</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multiple myeloma</topic><topic>Myeloma</topic><topic>Neoplasm Recurrence, Local</topic><topic>Patient outcomes</topic><topic>Public Health</topic><topic>Risk assessment</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival</topic><topic>Toxicity</topic><topic>Transplantation</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Autologous</topic><topic>Transplantation, Homologous</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Costa, Luciano J.</creatorcontrib><creatorcontrib>Iacobelli, Simona</creatorcontrib><creatorcontrib>Pasquini, Marcelo C.</creatorcontrib><creatorcontrib>Modi, Riddhi</creatorcontrib><creatorcontrib>Giaccone, Luisa</creatorcontrib><creatorcontrib>Blade, Joan</creatorcontrib><creatorcontrib>Schonland, Stefan</creatorcontrib><creatorcontrib>Evangelista, Andrea</creatorcontrib><creatorcontrib>Perez-Simon, Jose A.</creatorcontrib><creatorcontrib>Hari, Parameswaran</creatorcontrib><creatorcontrib>Brown, Elizabeth E.</creatorcontrib><creatorcontrib>Giralt, Sergio A.</creatorcontrib><creatorcontrib>Patriarca, Francesca</creatorcontrib><creatorcontrib>Stadtmauer, Edward A.</creatorcontrib><creatorcontrib>Rosinol, Laura</creatorcontrib><creatorcontrib>Krishnan, Amrita Y.</creatorcontrib><creatorcontrib>Gahrton, Gösta</creatorcontrib><creatorcontrib>Bruno, Benedetto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Costa, Luciano J.</au><au>Iacobelli, Simona</au><au>Pasquini, Marcelo C.</au><au>Modi, Riddhi</au><au>Giaccone, Luisa</au><au>Blade, Joan</au><au>Schonland, Stefan</au><au>Evangelista, Andrea</au><au>Perez-Simon, Jose A.</au><au>Hari, Parameswaran</au><au>Brown, Elizabeth E.</au><au>Giralt, Sergio A.</au><au>Patriarca, Francesca</au><au>Stadtmauer, Edward A.</au><au>Rosinol, Laura</au><au>Krishnan, Amrita Y.</au><au>Gahrton, Gösta</au><au>Bruno, Benedetto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>55</volume><issue>9</issue><spage>1810</spage><epage>1816</epage><pages>1810-1816</pages><issn>0268-3369</issn><issn>1476-5365</issn><eissn>1476-5365</eissn><abstract>Contrary to tandem autologous transplant (auto-auto), autologous followed by reduced intensity conditioning allogenic transplantation (auto-allo) offers graft-versus-myeloma (GVM) effect but with higher toxicity. Trials comparing these two strategies relied on availability of HLA-matched sibling donors for arm allocation (biological randomization) and yielded conflicting results. A pooled analysis of multiple trials with extended follow up provides an opportunity to compare these strategies. We obtained individual patient data from participants of four trials comparing auto-auto vs. auto-allo after induction therapy. There were 899 patients in auto-auto and 439 in auto-allo. Median follow up of survivors was 118.5 months. Median overall survival (OS) was 78.0 months in auto-auto and 98.3 months in auto-allo (HR = 0.84,
P
= 0.02). OS was 36.4% vs. 44.1% at 10 years (
P
= 0.01) for auto-auto and auto-allo, respectively. Progression-free survival was also improved in auto-allo (HR = 0.84,
P
= 0.004). Risk of non-relapse mortality was higher in auto-allo (10 year 8.3% vs. 19.7%,
P
< 0.001), while risk of disease progression was higher in auto-auto (10 year 77.2% vs. 61.6%,
P
< 0.001). Median post relapse survival was 41.5 months in auto-auto and 62.3 months in auto-allo (HR = 0.71,
P
< 0.001). This supports the existence of durable GVM effect enhancing myeloma control with subsequent therapies.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32286506</pmid><doi>10.1038/s41409-020-0887-4</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5362-2469</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2020-09, Vol.55 (9), p.1810-1816 |
| issn | 0268-3369 1476-5365 1476-5365 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_472036 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SWEPUB Freely available online; SpringerLink Journals - AutoHoldings |
| subjects | 692/308/2779/109/1942 692/699/67/1059/2325 692/699/67/1990/804 Autografts Care and treatment Cell Biology Clinical trials Disease-Free Survival Graft vs Host Disease Health risks Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Histocompatibility antigen HLA Humans Induction therapy Internal Medicine Medicine Medicine & Public Health Multiple myeloma Myeloma Neoplasm Recurrence, Local Patient outcomes Public Health Risk assessment Stem cell transplantation Stem Cells Survival Toxicity Transplantation Transplantation Conditioning Transplantation, Autologous Transplantation, Homologous Transplants & implants |
| title | Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T18%3A53%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20survival%20of%201338%20MM%20patients%20treated%20with%20tandem%20autologous%20vs.%20autologous-allogeneic%20transplantation&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Costa,%20Luciano%20J.&rft.date=2020-09-01&rft.volume=55&rft.issue=9&rft.spage=1810&rft.epage=1816&rft.pages=1810-1816&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-020-0887-4&rft_dat=%3Cgale_swepu%3EA633782930%3C/gale_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2437641495&rft_id=info:pmid/32286506&rft_galeid=A633782930&rfr_iscdi=true |